Sanofi-Aventis Q3 Results - Q3 Top Pharma Company Earnings Reports

View Sanofi-Aventis' Q3 Earnings Report

Highlights

• Good performances from Lovenox(R) (+13.7%) and Lantus(R) (+21.7%) across all three geographic regions, continuation of strong uptrend in the presence of Plavix(R) in the United States (+11.3%) and Japan (+50.3%)
• Sales growth of 20.9% in emerging markets
• Strong growth for the Pentacel(R) and Menactra(R) vaccines; substantial proportion of seasonal and A/H1N1 vaccines sales anticipated in the fourth quarter
• OTC sales up 26.3%
• Launch of Multaq(R) in the United States on target; positive opinion from the CHMP in Europe, and approval in Canada and Switzerland
• Impact of competition from generics of Eloxatin(R) in the United States and Plavix(R) in some European countries more than offset by growth drivers

Check out Sanofi-Aventis' current earnings estimates from CNN Money

Sanofi-Aventis' Website: http://www.Sanofi-Aventis.us

Related Articles:
No more pajamas for Sanofi analysts
Sanofi fights generics makers over Taxotere
Sanofi vet group plots $70M China expansion
Sanofi to launch copycat Plavix
Sanofi CEO promises more deals